ANAVEX 2-73 Restores Mitochondrial Functionality, Blocks Cell Death and Oxidative Stress, Preventing Onset of Alzheimer’s Disease

New data presented at International Conference on Alzheimer’s and Parkinson’s Diseases Vancouver, BC — March 12, 2013 — Anavex Life Sciences Corp. (“Anavex”) (OTCQB: AVXL) today announced more promising new data for ANAVEX 2-73, the company’s lead drug candidate for Alzheimer’s disease. In a scientific study conducted in France at the University of Montpellier and…